An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules

Robust preclinical testing is essential to predict clinical safety and efficacy and provide data to determine safe dose for first-in-man studies. There are a growing number of examples where the preclinical development of drugs failed to adequately predict clinical adverse events in part due to thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Harper, Jane, Adams, Katherine J., Bossi, Giovanna, Wright, Debbie E., Stacey, Andrea R., Bedke, Nicole, Martinez-Hague, Ruth, Blat, Dan, Humbert, Laure, Buchanan, Hazel, Le Provost, Gabrielle S., Donnellan, Zoe, Carreira, Ricardo J., Paston, Samantha J., Weigand, Luise U., Canestraro, Martina, Sanderson, Joseph P., Botta Gordon-Smith, Sophie, Lowe, Kate L., Rygiel, Karolina A., Powlesland, Alex S., Vuidepot, Annelise, Hassan, Namir J., Cameron, Brian J., Jakobsen, Bent K., Dukes, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188753/
https://www.ncbi.nlm.nih.gov/pubmed/30321203
http://dx.doi.org/10.1371/journal.pone.0205491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188753/
https://www.ncbi.nlm.nih.gov/pubmed/30321203
http://dx.doi.org/10.1371/journal.pone.0205491

Ejemplares similares